50 filings analyzed. Top movers: Loop Industries, Inc., Xenetic Biosciences, Inc., Rain Enhancement Technologies Holdco, Inc., SAN JUAN BASIN ROYALTY TRUST, Amesite Inc..
8-K
Loop Industries, Inc.
On November 9, 2026, Loop Industries received notice of failure to satisfy continued listing requirements. The filing indicates a delisting or transfer of listing event under Item 3.01 of Form 8-K, though specific regulatory deficiencies and remediation timelines are not detailed in the extracted filing summary provided.
▼ Likely negative
· significance 92 · 8-K Agent
8-K
Xenetic Biosciences, Inc.
Xenetic Biosciences (market cap ~$5.1M) announced a definitive share exchange agreement to acquire Santersus AG in an all-stock transaction expected to close Q1 2027, creating a Nasdaq-listed clinical-stage company focused on targeting neutrophil extracellular traps (NETs). The combined entity will be named Santersus Bio, Inc. (ticker: SNTS) and will combine Xenetic's DNase platform with Santersus's NucleoCapture platform, including four first-in-class programs with two FDA Breakthrough Device Designations in sepsis and systemic lupus erythematosus. Q3 2026 financials showed royalty revenue of $0.7M (down 29% YoY), R&D expenses of $0.5M (down 31%), G&A expenses of $1.9M (up 138% due to transaction costs), net loss of $1.7M ($0.72/share), and cash of $5.8M.
▲ Likely positive
· significance 92 · 8-K Agent
8-K
Rain Enhancement Technologies Holdco, Inc.
Rain Enhancement Technologies Holdco, Inc. (public market cap ~$7.3M) has signed a merger agreement to acquire Tensor Networks, Inc., effective November 12, 2026. Tensor Networks shareholders will receive Parent Class A Common Stock at an exchange ratio calculated from Tensor's $180M equity valuation divided by Parent's $20M valuation (minus remaining Parent debt post-restructuring). The deal requires shareholder approval and includes a reverse stock split, board/management changes, and customary closing conditions.
▲ Likely positive
· significance 92 · 8-K Agent
10-Q
SAN JUAN BASIN ROYALTY TRUST
San Juan Basin Royalty Trust (46.6M units outstanding) has received zero royalty income for 17 consecutive months (May 2024–September 2026) due to $12.6M in cumulative excess production costs ($9.4M net to trust) incurred by operator Hilcorp during 2024–2025 horizontal well drilling. Natural gas production declined 14.6% YoY; prices fell from $2.63/Mcf to $2.05/Mcf (9M). Trust depleted $1.8M cash reserves by May 2025, established $2M line of credit (May 2025, 8% interest, matures May 2027), and has drawn $1.08M as of Q3 2026. Trust corpus eroded from $2.29B (Dec 2025) to $1.60B (Sept 2026). Trustee explicitly states 'substantial doubt about ability to continue as going concern.'
▼ Likely negative
· significance 92 · Periodic Agent
8-K
Amesite Inc.
Amesite Inc. filed an 8-K on November 13, 2026, reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing does not disclose the specific listing standard violated, the exchange involved, cure period, or remediation actions. No dollar amounts, dates of non-compliance, or detailed circumstances are provided in the filing text.
▼ Likely negative
· significance 92 · 8-K Agent
8-K
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Creative Medical Technology Holdings (market cap ~$4.6M) received notice of delisting or failure to satisfy continued listing rule or standard on 2026-11-10, reported in 8-K filing dated 2026-11-13. The filing does not specify which exchange rule was violated, the remediation period, or the specific action required. Item 3.01 indicates a delisting notice or transfer of listing event, but no financial amounts, counterparties, or concrete remedial actions are disclosed in the available text.
▼ Likely negative
· significance 92 · 8-K Agent
8-K
PSQ Holdings, Inc.
PSQ Holdings, Inc. filed Form 8-K on November 13, 2026 (reporting period November 9, 2026) reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The filing provides no specific details regarding which exchange issued the notice, which listing standard(s) were not satisfied, timeline for remediation, or specific deficiency amounts.
▼ Likely negative
· significance 92 · 8-K Agent
8-K
FiEE, Inc.
FiEE, Inc. (market cap ~$6.0M) reported nine-month 2026 revenue of $9.6M versus $2.0M in 2025—a 382% increase—driven by new SaaS MCN digital services (939 customers, $3.7M revenue), software services ($2.3M revenue, 32 customers, $4.1M contract backlog), and phygital art advisory services ($3.5M revenue, 601 individual + 5 corporate clients). Net income swung to $3.6M profit from $1.3M loss YoY. Cash rose to $5.2M from $3.1M; accounts receivable ballooned to $4.6M from $2.1M. Gross margin compressed to 76.3% from 83.0% due to higher amortization and service-mix shift.
▲ Likely positive
· significance 92 · 8-K Agent
8-K
CN Healthy Food Tech Group Corp.
CN Healthy Food Tech Group Corp. filed an 8-K on November 13, 2026 reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing indicates the company has received notice of failure to meet continued listing standards, though specific violations, remediation timeline, or exchange details are not disclosed in the available text.
▼ Likely negative
· significance 92 · 8-K Agent
8-K
Singularity Future Technology Ltd.
On November 9, 2026, Singularity Future Technology Ltd. (public market cap ~$4.3M) received notice of delisting or failure to satisfy continued listing rules on its exchange. The 8-K Item 3.01 filing discloses the delisting notice and potential transfer of listing. No specific dollar amounts, counterparties, or remediation details are provided in the filing.
▼ Likely negative
· significance 92 · 8-K Agent
8-K
INNOVATE Corp.
INNOVATE Corp. (market cap ~$27.2M) completed two major dispositions: (1) Broadcasting to CONX on Sept 1, 2026, retaining 25% equity method interest valued at $57.6M and a call option for 15% more (max $45M) expiring 18 months out; and (2) DBMG to IES on Oct 5, 2026, receiving ~$413M cash plus 430,974 IES shares (~$138.4M at Sept 30). Company redeemed $325M of 10.50% 2027 Senior Notes on Oct 15, 2026. Concurrently increased ATM shelf from $31M to $50M maximum offering price (Nov 13, 2026). Pro forma results show company reduced to minimal operating base with $5M revenue post-dispositions.
▼ Likely negative
· significance 92 · 8-K Agent
8-K
Q/C TECHNOLOGIES, INC.
Q/C Technologies filed Form 8-K on November 13, 2026 reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing indicates the company has failed to meet exchange listing requirements. Specific details regarding which exchange, which listing standards were not met, remediation timeline, or financial metrics are not disclosed in the header text provided.
▼ Likely negative
· significance 92 · 8-K Agent
S-1
SHF Holdings, Inc.
SHF Holdings filed an S-1 to permit selling stockholders to resell up to 115,705,691 common shares: 115,417,259 shares from conversion of Series B Convertible Preferred Stock (issued Sept 30, 2025 at $0.1210/share conversion price) and 288,432 warrant shares (exercise price $18.6336). This represents a delayed or continuous secondary offering. The company also completed a 1-for-12 reverse stock split effective September 30, 2026.
▼ Likely negative
· significance 92 · Registration Agent
8-K
INTERLINK ELECTRONICS INC
Interlink Electronics Inc. (market value ~$8.2M) entered into an at-the-market (ATM) issuance sales agreement with A.G.P./Alliance Global Partners on November 13, 2026, authorizing the sale of up to $7,200,000 of common stock. The company will pay the agent a 3.0% transaction fee on gross proceeds. Shares will be sold on Nasdaq at market prices via the agent acting as sales agent. The agreement is effective for 12 months or until the maximum amount is sold.
▼ Likely negative
· significance 88 · 8-K Agent
8-K
Datavault AI Inc.
Datavault AI Inc. (market cap ~$47.5M) will be delisted from Nasdaq effective November 17, 2026, due to failure to maintain the $1.00 minimum bid price and closure of 10 consecutive sub-$0.10 trading days. The stock will trade on OTC markets instead. The company intends to request a Nasdaq Hearings Panel hearing to appeal and present a compliance plan to regain listing, with no assurance of success.
▼ Likely negative
· significance 87 · 8-K Agent
8-K
Rezolute, Inc.
Rezolute announced that its Phase 3 upLIFT study of ersodetug achieved its primary efficacy endpoint on November 5, 2026. Of 16 enrolled participants, 13 met the responder criterion (≥50% reduction in glucose infusion rate from baseline), exceeding the statistical threshold of 9 responders (56%) required for significance; 12 of these also achieved complete IV glucose discontinuation. Topline results with full statistical analysis are expected by mid-December 2026, with FDA pre-BLA meetings planned for Q1 2027 for both tumor HI and congenital HI indications.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
Quantum Cyber N.V.
Quantum Cyber N.V. (market cap ~$5.7M) reported its first revenue of $966,833 in Q3 2026 from the Arcade Metal Stamping business acquired July 15, 2026. CEO David Lazar committed $8.0 million in funding through November 30, 2027. The company expanded Project LightShift quantum antenna license field of use to include maritime and law enforcement applications (November 6, 2026 amendment), installed an 80-unit 3D printing farm at Bridgeport facility, and settled a legacy Boustead Securities claim for $250,000. Shareholders' equity increased 2,600% year-to-date to $16.2 million (from $0.6 million at year-end 2025), largely from $15.2 million in warrant exercise proceeds.
▲ Likely positive
· significance 78 · 8-K Agent
8-K/A
HeartSciences Inc.
Fortitude Mining Holdings, Inc. (a digital asset mining company owned by Digital Currency Group) entered into a merger agreement with HeartSciences Inc. in June 2026, with closing expected in Q4 2026. Under the deal structure, Fortitude will contribute its assets to HeartSciences in exchange for voting and economic shares, plus a $2M cash contribution. DCG will retain ~94% voting control post-close on a fully diluted basis. Separately, Fortitude secured a $70M credit facility from DCG (increased from initial $26M), used primarily to fund $31.5M in Zcash mining equipment purchases from Bitmain and a $20M deposit on next-generation Zcash miners under a $100M LOI with Bitmain.
— Neutral
· significance 78 · 8-K Agent
SCHEDULE 13D/A
Mega Fortune Co Ltd
On November 12, 2026, Mericorn Company Limited (BVI entity) transferred 1,475,000 ordinary shares of Mega Fortune Co Ltd (MGRT, Nasdaq-listed) to Wang Zixi for no consideration. This represents approximately 10.7% of MGRT's outstanding shares. The shares transferred free of encumbrances, with immediate closing and transfer agent registration to follow.
— Neutral
· significance 78 · Ownership Agent
10-Q
Lifeward Ltd.
Almog Adar (CFO) terminated Aug 10, 2026, effective Sept 30, 2026, receiving ~$16K accrued PTO, salary continuation for 6 months, target bonus for 2026 (amount unspecified), and COBRA subsidy for 6 months. Mark Grant (CEO/President) resigned Aug 31, 2026, receiving salary through that date and a $40K consulting fee for Sept 2026 (20 hrs/month max). Both signed separation agreements with 12-month non-compete and broad release of claims. Josh Hexter is interim CEO; Ronen Tsimerman is CFO as of the filing date (Nov 13, 2026).
▼ Likely negative
· significance 78 · Periodic Agent
8-K
Greenland Energy Co
Greenland Energy agreed to acquire 80 Mile plc (AIM: 80M) in an all-share transaction where 80 Mile shareholders receive 0.0079485 Greenland Energy shares per 80 Mile share, valuing 80 Mile at ~£74M (~$98.5M USD at stated rates) and representing a 71% premium to 80 Mile's September 7, 2026 closing price. Upon completion, Greenland and 80 Mile shareholders will each own ~50% of the combined company. The transaction consolidates 100% ownership of the Jameson Land Basin licenses in Greenland and combines 80 Mile's portfolio with Greenland Energy's $37.4M cash position (as of June 30, 2026). Both boards unanimously recommend approval, subject to shareholder votes, court sanction, and regulatory consents.
▲ Likely positive
· significance 78 · 8-K Agent
8-K
Aptera Motors Corp
Aptera Motors reported Q3 2026 GAAP net loss of $14.0M and 9-month loss of $35.0M on total assets of $32.4M. The company raised $6.0M gross in Q3 (warrant transaction) and $23.1M total in 9M 2026 (public offering + warrant exercises + $2.3M equity line), ending Q3 with $9.2M cash including $4.1M in refundable reservation fees. In August 2026, Aptera entered a Strategic Partnership Agreement with Shanghai Launch Automotive Technology covering up to RMB 300M in manufacturing/engineering services (two-thirds cash, one-third warrants), ordered initial production parts, and estimates $25M to reach series production start and $65M total to reach 500 units/month production. Company explicitly states substantial doubt about going concern has not been alleviated and existing cash is insufficient for next 12 months.
▼ Likely negative
· significance 78 · 8-K Agent
8-K
NEXTNRG, INC.
On November 10, 2026, NEXTNRG, Inc. received a notice of failure to satisfy continued listing standards. The filing reports Item 3.01 (delisting notice) and Item 9.01 (financial statements/exhibits) but does not specify which exchange, the precise listing standard violated, the remediation period, or financial details. No counterparties, dollar amounts, or remedial actions are disclosed in the available filing text.
▼ Likely negative
· significance 78 · 8-K Agent
8-K
Greenland Technologies Holding Corp.
Greenland Technologies (market cap ~$22M) received a Nasdaq notification on November 10, 2026, that its Class A ordinary shares have failed to maintain the required $1.00 minimum bid price over 30 consecutive business days (September 29 – November 9, 2026). The company has 180 calendar days (until May 10, 2027) to regain compliance by achieving a $1.00+ closing bid price for 10 consecutive business days, or faces potential delisting; management is considering a share consolidation among other options.
▼ Likely negative
· significance 78 · 8-K Agent
S-1
WESTWATER RESOURCES, INC.
On November 10, 2026, Westwater Resources (market cap ~$45.8M) executed a Purchase Agreement with Lincoln Park Capital Fund, LLC granting Lincoln Park the right to purchase up to $50 million of common stock over 24 months at discounted market prices. Westwater issued 600,000 Initial Commitment Shares immediately (no cash received) and may issue up to 1.4 million Additional Commitment Shares and up to 24.1 million purchase shares. The agreement is subject to NYSE American Exchange Cap (19.99% of outstanding shares, or 26.1M shares) and 9.99% beneficial ownership caps. This prospectus registers 26.1M shares for resale by Lincoln Park.
▼ Likely negative
· significance 78 · Registration Agent
8-K
VIVMARK RESIDENTIAL
On August 17, 2026, Equity Residential (now Vivmark Residential) completed a merger with AvalonBay Communities at a 2.793 share exchange ratio, with AvalonBay shareholders receiving ~772.7M Vivmark shares. Total consideration: $24.7B. Legacy AvalonBay shareholders own 51%; legacy Equity Residential shareholders own 49%. AvalonBay is the accounting acquirer. No goodwill recognized; all $24.7B allocated to identifiable net assets ($32.8B real estate, $9.0B liabilities assumed). Pro forma combined rental income: $4.7B (9M 2026), $6.1B (FY 2025).
— Neutral
· significance 78 · 8-K Agent
8-K
Annovis Bio, Inc.
Annovis closed an underwritten public offering on November 6, 2026, raising $21.0 million gross proceeds (with the Board Chairman contributing $5.0 million). The company's pivotal Phase 3 DUET-AD trial in Alzheimer's disease is fully enrolled with 862 patients; last patient/last visit scheduled December 31, 2026, database lock February 8, 2027, and topline 6-month results in March 2027. Cash and equivalents fell from $19.5M (Dec 2025) to $2.8M (Sept 2026); the $21M offering is intended to fund operations through the 6-month data readout.
— Neutral
· significance 78 · 8-K Agent
8-K
Newton Golf Company, Inc.
Newton Golf reported Q3 2026 net sales of $1.4M (down 47% YoY from $2.6M), net loss of $1.2M ($0.23/share), and cash of only $513K at quarter-end. Post-quarter, the company raised ~$3.0M net from equity/debt conversions (ATM sales of 1.3M shares at $1.18, private placement of 968K shares at $1.24, $500K preferred investment, and $1.0M debt conversion into 211.7K common + 7.9K preferred shares), bringing pro forma stockholders' equity to ~$5.2M. However, management explicitly stated substantial doubt about going concern; Nasdaq notified the company on October 6 of non-compliance with $2.5M minimum equity requirement; a Nasdaq hearing is scheduled for November 12, 2026.
▼ Likely negative
· significance 78 · 8-K Agent
8-K
Hall Chadwick Acquisition Corp
Hall Chadwick Acquisition Corp. (HCAC, $211.6M assets) announced SEC effectiveness of its Form S-4 registration statement for merger with REEcycle Holdings, a rare-earth recycling company. The transaction values REEcycle at $350M equity plus $50M earnout ($400M total), with shareholder vote scheduled December 10, 2026, and anticipated closing before year-end 2026. REEcycle has received $5.1M from U.S. Defense Production Act Title III program and is developing proprietary technology to recover rare-earth elements from end-of-life permanent magnets.
▲ Likely positive
· significance 78 · 8-K Agent
10-Q
CHEETAH NET SUPPLY CHAIN SERVICE INC.
Cheetah Net Supply Chain Service Inc. (a $3.5M market-cap company) entered two loan agreements as lender to Asia Finance Investment Limited: (1) $700,000 at 5% annual interest, signed July 2, 2026, due July 2, 2027; (2) $1,520,000 at 5% annual interest, signed August 27, 2026, due August 27, 2027. Total deployed capital: $2,220,000 (63% of company market value). Both loans carry standard covenants, 7.5% default rate, and North Carolina governing law. Borrower CEO is Peizhe Han; Lender CEO is Huan Liu (also serving as interim CFO).
▼ Likely negative
· significance 78 · Periodic Agent
8-K/A
Intellia Therapeutics, Inc.
Intellia's lonvoguran ziclumeran (lonvo-z), a one-time in vivo CRISPR gene therapy for hereditary angioedema (HAE), achieved its Phase 3 primary endpoint: 62% mean attack-rate reduction weeks 5–28 vs. placebo (p<0.0001), with 87% attack-free weeks (95% CI: 78–93%). The FDA accepted the biologics license application on September 3, 2026, with priority review and a PDUFA goal date of March 10, 2027. Of 93 patients dosed with lonvo-z 50 mg across trials, 100% remain prophylaxis-free with durable effect up to 4 years; 2 Grade 3 serious adverse events occurred (unrelated pulmonary embolism and appendicitis). Intellia has pre-positioned a commercial team, payer outreach (280M+ lives), and authorized treatment center network in anticipation of approval.
▲ Likely positive
· significance 78 · 8-K Agent
4
STARWOOD PROPERTY TRUST, INC.
CEO, Chairman of the Board STERNLICHT BARRY S (STWD) bought 1.2M shares (~$14.7M) on the open market (45% of holdings). Open-market insider purchase — historically a bullish signal.
▲ Likely positive
· significance 78 · Insider Agent
8-K
Digi Power X Inc.
Digi Power X reported Q3 2026 revenue of $12.25M (up 85% QoQ, 50% YoY), with AI revenue of $5.66M (up 400% QoQ from $1.08M; nil in Q3 2025). The company secured a $402M ten-year take-or-pay colocation contract with Cerebras for Columbiana Phase 1 (15 MW, $40M annual average), with Phase 2 conditional at $1.07B total. Phase 1 tenant access expected December 15, 2026; billing begins January 2027. A $200M debt facility syndicated by Goldman Sachs is expected to close Q4 2026. Cash position: $119.6M with no debt; 2027 capex planned at $350M funded via customer deposits and contract-backed debt. 2027 revenue run-rate target: $250–300M annualized by Q3 2027.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
IMMUNIC, INC.
Immunic reported Q3 2026 results with $131.96M cash (up from $15.48M at year-end 2025, funded by February 2026 private placement). Lead program vidofludimus calcium in twin Phase 3 ENSURE trials (1,121 and 1,100 relapsing MS patients enrolled) remains on schedule for December 2026 top-line data; if positive, NDA submission planned mid-2027 with potential approval in 2028. Phase 3 PROTECT-MS progressive MS trial initiating with first patient expected H1 2027. Company added Chief Data/Digital Officer (Sept 2026) and Chief People Officer (Oct 2026); board added CFO Elena Ridloff. Nine-month operating expenses reached $111.9M; net loss $109.0M ($2.83/share) on 38.5M weighted-average shares. Cash runway extends to late 2027.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
PAVmed Inc.
PAVmed reported Q3 2026 results: Lucid Diagnostics achieved full Medicare reimbursement for EsoGuard (began October 2026, record month 1,800+ tests, $1.2M Q3 revenue); Veris Health completed implantable monitor design freeze and initiated 90-day GLP animal study (early 2027 FDA 510(k) submission target); PortIO and Octeris in FDA pre-submission discussions. PAVmed Q3 operating expenses $6.8M, non-GAAP adjusted loss $(0.19)/share; cash position $8.9M (vs. $1.5M end-2025). As Lucid's largest shareholder, PAVmed benefits directly from Lucid's revenue growth.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
PDS Biotechnology Corp
PDS Biotech announced initial closing of a $22.3M PIPE financing led by Nant Capital LLC (Dr. Soon-Shiong), with a contingent milestone closing tied to PDS0301 Phase 3 FDA submission. NantWorks received a one-year exclusive option to license PDS0101. Cash declined from $26.7M (Dec 2025) to $15.2M (Sept 2026); Q3 net loss was $7.6M ($0.11/share). The company appointed Soon-Shiong and three pharma veterans to the board.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Biofrontera Inc.
Biofrontera reported Q3 2026 net product revenue of $9.1M (+29.8% YoY) and nine-month revenue of $31.2M (+26.6% YoY). On September 9, 2026, the FDA approved Ameluz for superficial basal cell carcinoma (sBCC), the first PDT approved for cancerous skin tumors. On September 14, 2026, U.S. Customs and Border Protection ruled the redesigned RhodoLED XL-C lamp complies with import requirements, ending the ITC exclusion order. Gross margin improved to 74.4% in Q3 (vs. 70.7% prior year) due to lower Ameluz cost structure from the October 2025 strategic transaction with Biofrontera AG. Net loss narrowed to $6.4M for Q3 (vs. $6.6M prior year) and $11.8M for nine months (vs. $16.2M prior year). Cash declined to $3.2M as of September 30, 2026 (from $6.4M at year-end 2025); convertible notes of $4.7M mature November 2027.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Cineverse Corp.
Cineverse reported Q2 FY2027 revenue of $26.0M (+110% YoY from $12.4M), driven by acquisitions of IndiCue and Giant Worldwide completed in Q4 FY2026, with technology/media services now 55% of revenue. Net income was $3.2M ($0.11 diluted EPS) versus $(5.7)M loss YoY; Adjusted EBITDA reached $1.7M, up $5.4M YoY and the third consecutive positive quarter. The company reaffirms FY2027 guidance of $115–$120M revenue and $10–$20M Adjusted EBITDA, with $9M of $10M cost reduction program achieved to date.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
MetaVia Inc.
MetaVia (Nasdaq: MTVA, ~$3M market cap) announced interim Phase 1 Part 3B results for DA-1726, a GLP-1/glucagon dual agonist: 68.1% placebo-adjusted liver fat reduction, 13.5% weight loss, and 0.24 pp HbA1c reduction at 16 weeks in 15 obese subjects with no new GI adverse events after week 9. The company appointed Sarah Browne, M.D. as Chief Medical Officer and plans a 48-week Phase 2 study in up to 150 subjects with MetALD/ALD starting H2 2027. Cash position was $8.8M as of September 30, 2026, with 9-month net loss of $13.8M ($2.36 per share, 5.8M weighted average shares).
▲ Likely positive
· significance 72 · 8-K Agent
10-Q
NOODLES & Co
On November 12, 2026, Noodles & Co amended its credit agreement with U.S. Bank (administrative agent), Huntington National Bank, and First Horizon Bank. Key changes: (1) Maturity extended to November 30, 2027 (from prior date); (2) Interest rate locked at 3.25% (SOFR) / 2.25% (Base) through January 29, 2027, then auto-increases to SOFR+7.00% if debt unpaid; (3) Extension fee of $750,000 paid immediately; (4) Milestone fee of $1,250,000 due if obligations unpaid by January 29, 2027; (5) All outstanding letters of credit to expire without renewal; borrower must post 105% cash collateral or obtain third-party replacements. Total revolving commitment: $120M ($52.8M U.S. Bank, $46.56M Huntington, $20.64M First Horizon).
▼ Likely negative
· significance 72 · Periodic Agent
8-K
FG Communities Holdings Inc.
FG Communities Holdings (market cap ~$13.2M) invested $10.0 million in privately held FG Communities, Inc. during Q3 2026 and completed two direct manufactured housing acquisitions in October 2026 (Garner, NC: 49 homesites; Mars Hill, NC: 29 homesites; 78 total) using cash on hand. Company ended Q3 with $35.1M cash, $55.3M stockholders' equity; repurchased ~$22.8M common stock and ~$7.2M preferred stock YTD through September 30, 2026.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Lifeward Ltd.
Lifeward reported Q3 2026 revenue of $5.4M (down 12% YoY from $6.2M), with AlterG growing 18% to $3.6M but ReWalk revenue falling 43% to $1.7M due to transition from direct sales to channel-partner distribution. Operating loss widened to $6.0M from $3.1M YoY; net loss was $5.1M ($1.32/share, 3.84M shares weighted average) vs. $3.2M prior year. Gross margin collapsed to 27.4% from 43.7% YoY, driven by FX, tariffs, and revenue-sharing payments to Oramed under the March 2026 Oratech acquisition. Cash position improved to $4.5M (Sept 30) from $2.2M (Dec 31), reflecting $18.5M in financing activities YoY.
▼ Likely negative
· significance 72 · 8-K Agent
8-K
REALLOYS INC.
REalloys (market cap ~$15.8M) executed a non-binding term sheet with the U.S. Army on November 3, 2026, for a heavy rare earth processing facility on ~200 acres at Tooele Army Depot, Utah, targeting dysprosium and terbium refining with a 50-year initial term. The company ended Q3 2026 with $116.2M cash (7.4x market cap), deployed $16.5M to SRC programs YTD, and targets North American rare earth metal production beginning 2027 and ~3,000 tonnes/year U.S. magnet production by 2030. Q3 net loss was $30.5M ($0.44/share), primarily driven by $25.3M non-cash stock-based compensation from the February 2026 Nasdaq listing.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Toppoint Holdings Inc.
Toppoint Holdings approved a 1-for-5 reverse stock split, reducing shares outstanding from 24.7M to approximately 4.94M, effective November 23, 2026. The action follows NYSE American's November 10 trading halt due to abnormally low share price and is intended to restore per-share price to meet continued listing standards. All stockholders are affected uniformly with no action required; fractional shares are rounded up.
▼ Likely negative
· significance 72 · 8-K Agent
8-K
CONSUMER PORTFOLIO SERVICES, INC.
Consumer Portfolio Services reported record Q3 2026 results: auto contract purchases surged 109% YoY to $815M, growing total managed portfolio to $4.84B (largest in company history). Net income rose 43.3% to $10.1M; diluted EPS grew 50% to $0.30. Shareholder equity increased to $324.5M from $309.5M at year-end 2025. Delinquencies fell 167 bps to 12.29%, annualized net charge-offs improved 75 bps to 7.26%, and auction recovery rate increased 328 bps to 32.0%. The company maintains 13,000 approved dealers across 47 states with 60 consecutive profitable quarters.
▲ Likely positive
· significance 72 · 8-K Agent
10-Q
AIR INDUSTRIES GROUP
On 29 October 2026, Air Industries Machining Corp. (subsidiary of Air Industries Group) modified its lease with Hope Horizon Bay Shore LLC / Bay Shore Horizon LLC for premises at 1479–1480 North Clinton Avenue, Bay Shore, NY. The lease term was extended to 31 December 2036. Tenant will use its $190,286.54 accumulated reserve fund plus $756,713.46 in landlord financing (total $947,000 project by CCM Roofing) to repair/replace the roof. Air Industries will repay the landlord loan at $6,305.94/month for 120 months (Jan 2027 – Dec 2036) in addition to existing $1,189/month reserve payments, totaling $7,494.95/month during repayment. Base monthly rent is $78,276.49 for months 1–60 of renewal term, then $80,624.79 for months 61–120. Tenant may terminate after 60 months (Jan 2032 onward) with 24 months' notice.
— Neutral
· significance 72 · Periodic Agent
8-K
TRex Bio, Inc.
TRexBio, a clinical-stage biotech focused on tissue Treg immunotherapy, completed a $133.5M IPO in October 2026 (9.5M shares at $14/share; net proceeds ~$119M), extending cash runway to H2 2029. Lead candidate TRB-061 showed positive Phase 1a proof-of-mechanism in healthy volunteers with no serious adverse events; Phase 1b atopic dermatitis data expected mid-2027. Secondary candidate TRB-071 advancing toward Phase 1 initiation in H1 2027.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Enveric Biosciences, Inc.
Enveric Biosciences reported Q3 2026 net loss of $2.5M ($0.57 per share) versus $3.4M in Q3 2025, with cash-on-hand of $5.6M as of September 30, 2026. The company completed IND-enabling ADMET studies for lead candidate EB-003 (non-hallucinogenic mescaline derivative) showing favorable absorption and reduced drug-drug interactions; preclinical qEEG study demonstrated brain penetration with activity pattern distinct from DMT; and secured U.S. patent allowance for EVM401 Series. IND submission planned with first-in-human Phase 1 trial to follow.
▲ Likely positive
· significance 72 · 8-K Agent
8-K
Bluejay Diagnostics, Inc.
Bluejay Diagnostics completed enrollment of 777 patients in its SYMON-II pivotal study (exceeding 750-patient target), with preliminary data showing 18% 28-day mortality. The company established an alternative manufacturing facility through Sanyoseiko ahead of the October 23, 2026 contractual deadline with Toray Industries and secured a distribution agreement with Lovell Government Services. As of September 30, 2026, Bluejay held $7.38M in cash (vs. $5.16M at year-end 2025), burned $5.09M in nine-month operating losses, and estimates runway through Q2 2027; FDA 510(k) submission is targeted for H1 2027.
▲ Likely positive
· significance 72 · 8-K Agent
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.